Viridian Therapeutics reported positive topline data from the phase 3 THRIVE clinical trial of veligrotug for the treatment of active thyroid eye disease.
The intravenously delivered anti-insulin-like growth factor-1 receptor antibody, formerly known as VRDN-001, achieved all primary and secondary endpoints, according to a press release. Patients treated with five infusions showed statistically significant improvement in measured signs and symptoms of thyroid eye disease (TED) at 15 weeks.
Patients treated with veligrotug had a proptosis responder rate of 70% compared with 5% in those who